Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enalapril and Folic Acid for CIN Prevention in Hypertensive Patients
NCT02575092Phase 3Completed
- Sponsor
- Fuling Central Hospital
- Start
- Nov 2015
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of folic acid in contrast-induced nephropathy (CIN), sponsored by Fuling Central Hospital. Started Nov 2015; status: completed.
02
Drugs
folic acid
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT02575092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575092.